# An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients

> **NCT01590823** · PHASE1 · COMPLETED · sponsor: **Nova Scotia Health Authority** · enrollment: 10 (actual)

## Conditions studied

- Blood Coagulation Disorders

## Interventions

- **DRUG:** Dabigatran Etexilate 110 mg

## Key facts

- **NCT ID:** NCT01590823
- **Lead sponsor:** Nova Scotia Health Authority
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2012-11-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590823, "An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01590823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*